-
1Academic Journal
المؤلفون: M. Khubutia Sh., V. Nikulina P., M. Godkov A., V. Syutkin E., O. Andreitseva I., A. Chzhao V., М. Хубутия Ш., В. Никулина П., М. Годков А., В. Сюткин Е., О. Андрейцева И., А. Чжао В.
المصدر: Transplantologiya. The Russian Journal of Transplantation; № 2 (2009); 25-31 ; Трансплантология; № 2 (2009); 25-31 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2009-0-2
مصطلحات موضوعية: immunosuppression, cyclosporine, tacrolimus, immunological results, иммуносупрессия, циклоспорин, такролимус, иммунологические результаты
وصف الملف: application/pdf
Relation: https://www.jtransplantologiya.ru/jour/article/view/260/322; Starzl T.E., Murase N., Abu-Elmagd K. et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003;361:1502—10.; Starzl T.E., Demetris A.J. Liver Transplantation. Chicago, IL; 1990.; Reding R. Steroid withdrawal in liver transplantation: benefits, risks and unanswered questions. Transplantation 2000;70:405—10.; Kasiske B.L., Chakkera H.A., Louis T.A., Ma J.Z. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol. 2000;11:1910—7.; Lerut J. Avoiding steroids in solid organ transplantation. Transpl Int 2003;16:213—24.; Lerut J., Mathys J., Verbaandert C. et.al. Tacrolimus monotherapy in liver transplantation one-year results of a prospective, randomized, double-blind, placebo. Ann Surg 2008;248:956—67.; Sherlock S., Dooley J. Diseases of the liver and biliary system. 11. Oxford: Blackwell Science Ltd; 2002.; Vilatoba M., Contreras J.L., Eckhoff D.E. New immunosuppressive strategies in liver transplantation: balancing efficacy and toxicity. Current Opin Organ Transplant 2003;8:139—45.; Wiesner R.H., Demetris A.J., Belle S.H. et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998;28:638—45.; Neuberger J., Adams D.H. What is the significance of acute liver allograft rejection? J Hepatol 1998;29:143—50.; Lowes J.R., Hubscher S.G., Neuberger J.M. Chronic rejection of the liver allograft. Gastroenterol Clin North Am 1993;22:401—20.; Ojo A.O., Held P.J., Port F.K. et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349: 931—40.; Kahan B.D. The limitations of calcineurin and mTOR inhibitors: new directions for immunosuppressive strategies. Transplant Proc 2002;34:130—3.; The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110—5.; Neuhaus P., Langrehr J.M., Williams R. et al. Tacrolimus-based immunosuppression after liver transplantation: a randomised study comparing dual versus triple low-dose oral regimens. Transplant Int 1997;10:253—61.; Ekberg H. Tailoring minimal immunosuppression long term. Transplant Proc 2003;35:755—7.; Schreuder T.C., Hübscher S.G., Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? Transpl Int 2009;22(2):144—52.; Duclos-Valle’e J.C. Recurrence of autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis after liver transplantation. Acta Gastroenterol Belg 2005;68 (3):331—6.; Washburn K., Speeg K.V., Esterl R. et al. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation 2001;72(10):1675—9.; Nancy Agmon-Levin MD1, Bat-sheva Porat Katz MD2 and Yehuda Shoenfeld MD FRCP1. Infection and primary biliary cirrhosis. IMAJ 2008;10:112—5.; https://www.jtransplantologiya.ru/jour/article/view/260